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Abstract
Background & Aims
The therapeutic benefits of mesenchymal stem cells (MSCs), such as homing ability, multi-
potent differentiation capacity and secretion of soluble bioactive factors which exert neuro-
protective, anti-inflammatory and immunomodulatory properties, have been attributed to
attenuation of autoimmune, inflammatory and neurodegenerative disorders. In this study,
we aimed to determine the earliest time point at which locally administered MSC-based
therapies avert enteric neuronal loss and damage associated with intestinal inflammation in
the guinea-pig model of colitis.
Methods
At 3 hours after induction of colitis by 2,4,6-trinitrobenzene-sulfonate (TNBS), guinea-pigs
received either human bone marrow-derived MSCs, conditioned medium (CM), or uncondi-
tioned medium by enema into the colon. Colon tissues were collected 6, 24 and 72 hours
after administration of TNBS. Effects on body weight, gross morphological damage,
immune cell infiltration and myenteric neurons were evaluated. RT-PCR, flow cytometry
and antibody array kit were used to identify neurotrophic and neuroprotective factors
released by MSCs.
Results
MSC and CM treatments prevented body weight loss, reduced infiltration of leukocytes into
the colon wall and the myenteric plexus, facilitated repair of damaged tissue and nerve
fibers, averted myenteric neuronal loss, as well as changes in neuronal subpopulations.
The neuroprotective effects of MSC and CM treatments were observed as early as 24 hours
after induction of inflammation even though the inflammatory reaction at the level of the
myenteric ganglia had not completely subsided. Substantial number of neurotrophic and
neuroprotective factors released by MSCs was identified in their secretome.
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Conclusion
MSC-based therapies applied at the acute stages of TNBS-induced colitis start exerting
their neuroprotective effects towards enteric neurons by 24 hours post treatment. The neu-
roprotective efficacy of MSC-based therapies can be exerted independently to their anti-
inflammatory effects.
Introduction
Chronic relapsing inflammation of the gastrointestinal (GI) tract is characteristic of inflamma-
tory bowel disease (IBD) which includes two pathologies, Crohn’s disease and ulcerative colitis.
The onset of IBD is concomitant with young adulthood and in its active stage presents through
abdominal pain, diarrhea, nausea/vomiting, constipation and weight loss [1, 2]. As the disease
progresses it leads to complications, such as fistulas, abscesses, strictures, perforation of the
bowel and toxic megacolon [3, 4].
The exact etiology of IBD remains unknown, although environmental factors, the immune
system, the microbiome and damage to the enteric nervous system (ENS) have been shown to
influence its pathophysiology [2, 5, 6]. The ENS intrinsically innervates the GI tract and is
responsible for monitoring and coordinating all aspects of gut function [7]. Clinical and experi-
mental studies have demonstrated that intestinal inflammation is associated with loss of enteric
neurons and destruction of nerve fibers [8–11], as well as functional changes in enteric neu-
rons, including hyperexcitability and altered neurotransmission [12–15]. Furthermore, colonic
inflammation affects changes in the neurochemical coding of myenteric neurons such as
choline acetyltransferase (ChAT) and neuronal nitric oxide synthase (nNOS) neurons, causing
disruption of GI functions [16–18]. Structural and functional changes in the ENS leading to
alterations of intestinal functions can persist long after the resolution of acute intestinal inflam-
mation [19, 20]. Damage to the ENS plays a role in the generation of IBD symptoms and
underlies disease progression [21]. Infiltration of immune cells to the level of the myenteric
and submucosal plexuses of the gut wall can be predictive of IBD recurrence [22, 23]. Together
these findings suggest that targeting enteric neurons may be beneficial in combating IBD
severity.
Currently, IBD treatments are focused towards suppressing inflammation with lifelong
medications, such as antibiotics, corticosteroids, biologics and other immunomodulatory
agents [24, 25]. Overall, current therapies have limited efficacy due to loss of patient’s respon-
siveness and severe side-effects [25]. Therefore, many IBD patients will undergo surgery for
treatment of refractory disease or specific complications, often requiring repeated surgeries
[25, 26]. Novel treatments for intestinal inflammation currently being investigated include the
manipulation of gut microbiota and cellular therapies [27–29].
Mesenchymal stem cells (MSCs) have demonstrated significant potential for clinical use in
a variety of inflammatory, autoimmune and nervous system diseases [30–32]. MSCs are multi-
potent cells that can be derived from many adult tissues and are capable of differentiating into
multiple lineages within the appropriate microenvironment, including cells of neuronal and
glial lineage [33–35]. Potential advantages of MSCs for cellular therapy include: ease of isola-
tion, in vitro expansion capacity, low immunogenicity, receptiveness to in vitro genetic modifi-
cation and a safe and feasible profile for transplantation into humans [36, 37]. Although not
completely understood, it is considered that MSCs may exert therapeutic effects via secretion
of biologically active molecules and factors that may have anti-inflammatory,
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immunomodulatory and neuroprotective effects [38–40]. Culture medium containing the
MSC secretome released during in vitro expansion (MSC-conditioned medium (CM)) has
demonstrated therapeutic potential in various pathologies [36].
Results from clinical trials in IBD patients with fistulae and luminal inflammation demon-
strate that MSC therapy is both safe and feasible [27, 28, 41–43]. Experimental models of colitis
have confirmed that MSCs migrate to sites of inflammation and exert their anti-inflammatory
actions for the restoration of epithelial barrier integrity and repair of damaged tissue [44–48].
While the competence of MSCs to repair tissue damage associated with intestinal inflamma-
tion has been verified, there is currently only one study that has examined the effects of MSC-
based therapies in attenuating inflammation-induced enteric neuropathy [18]. In this study,
bone marrow-derived MSCs (BM-MSCs) and CM, administered by enema, were effective in
protecting enteric neurons from 2,4,6-trinitrobenzene-sulfonate acid (TNBS)-induced inflam-
matory damage to the guinea-pig distal colon, as well as attenuating colonic dysmotility 7 days
post treatment. Previous studies in animal models of multiple sclerosis, spinal cord injury,
myocardial infarction, glaucoma and kidney injury reported that therapeutic effects of MSCs
occur as early as several hours to several days after administration [49–53]. Furthermore,
MSCs have been shown to exert neuroprotective, anti-inflammatory and immunomodulatory
effects in experimental traumatic brain injury 2–3 days post administration [54, 55]. These
studies suggest that long-term engraftment of MSCs is not required for their efficacy and that
less than 7 days is sufficient to generate a therapeutic effect. While it was shown that MSCs alle-
viate enteric neuropathy associated with colitis 7 days after administration [18], the time point
at which MSCs initiate their therapeutic effects has not been determined. Therefore, the aim of
this study was to investigate at which time point following induction of colitis human
BM-MSCs and CM become beneficial in protecting and repairing enteric neurons. This infor-
mation will assist future investigations into the mechanisms of enteric neuroprotection by
MSCs.
Materials and Methods
Animals
Male and female Hartley guinea-pigs weighing 140–280g (n = 69) were attained from South
Australian Health and Medical Research Institute and randomly assigned to experimental
groups. All guinea-pigs were housed in a temperature-controlled environment with 12 hour
day/night cycles and free access to food and water. All animal experiments in this study com-
plied with the guidelines of the National Health and Medical Research Council (NHMRC)
Australian Code of Practice for the Care and Use of Animals for Scientific Purposes and were
approved by the Victoria University Animal Experimentation Ethics Committee (ethics num-
ber AEETH12-012). All efforts were made to minimize animal suffering.
MSC culture
Passage 4 human BM-MSC cell lines BM-7025 and BM-7081 (Tulane University) were charac-
terized for their expression of surface antigens, differentiation potential, and colony forming
ability as previously described [18]. All tests confirmed that MSCs used in this study met crite-
ria for defining in vitroMSC cultures proposed by the International Society for Cellular Ther-
apy (ISCT) [56]. Cells were plated at an initial density of 60 cells/cm2 and incubated in
complete culture medium; minimum essential medium (α-MEM) supplemented with 16.5%
MSC qualified fetal bovine serum (FBS) (validated by Life Technologies and is tested to suc-
cessfully support the differentiation and culture of human MSCs according to ISCT guide-
lines), 100 U/mL penicillin/streptomycin, and 100X GlutaMAX (all purchased from GIBCO,
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Life Technologies) at 37°C. Medium was replenished every 48–72 hours for 10–14 days until
the cells were 70–85% confluent (maximum). MSCs were rinsed in 5mL sterile phosphate buff-
ered solution (PBS) (1X) prior to incubation with 3mL trypsin/ethylenediaminetetraacetic acid
(EDTA) solution (TrypLE Select; GIBCO, Life Technologies) for 3 minutes at 37°C to detach
cells. Enzymatic activity was neutralized by 8mL of stop solution (α-MEM + 5% FBS) and
MSCs were collected and centrifuged at 450 g for 5 minutes at room temperature. Cells were
then re-suspended in fresh culture medium and counted using a light microscope. CM was
aspirated following a minimum of 48 hours incubation with MSCs and used for in vivo experi-
ments. Unconditioned medium (UCM) is the culture medium described above, but not
exposed to MSCs.
Induction of TNBS colitis
For induction of colitis, 2,4,6-trinitrobenzene-sulfonic acid (TNBS) (Sigma) was dissolved in
30% ethanol to a concentration of 30mg/kg [15]. A total volume of 300μL was instilled by
enema into the lumen of the colon through a lubricated silicone catheter approximately 7cm
proximal to the anus. For TNBS administration, guinea-pigs were anesthetized with isoflurane
(induced at 4%, maintained on 1–4% isoflurane in O2). Sham-treated guinea-pigs underwent
the same procedure excluding TNBS administration.
Treatment with MSCs, CM and UCM
Guinea-pigs in MSC-treated, CM-treated, and UCM-treated groups were anesthetized with
isoflurane 3 hours after TNBS administration and administered 1x106 MSCs, or 300μL CM, or
300μL UCM by enema into the colon via a silicone catheter. In hapten-induced colitis, ethanol
serves to disrupt the mucosal barrier allowing TNBS to infiltrate the underlying colonic layers
and initiate inflammation. The peak of ethanol-induced epithelial damage occurs at 3 hours
[57], therefore this time point was selected for the administration of MSC-based therapies. Ani-
mals were held at an inverted angle following MSC-based treatments to prevent leakage from
the rectum. Guinea-pigs were weighed and monitored daily following treatment. Animals were
culled via stunning (a blow to the occipital region) and exsanguination [13, 14] 6, 24 and 72
hours after induction of colitis or sham treatment. Segments of the distal colon were collected
for histological and immunohistochemical studies.
Tissue preparation
Colon tissues were cut open along the mesenteric border, stretched and pinned flat with the
mucosal side up for wholemount preparations; samples for cross sections were not stretched.
Tissue samples were fixed overnight at 4°C in Zamboni’s fixative (2% formaldehyde and 0.2%
picric acid) and subsequently washed in dimethyl sulfoxide (DMSO) (Sigma-Aldrich) and PBS
to remove fixative. Samples for histology were fixed in 10% buffered formalin solution and
stored in 70% ethanol until embedding.
Immunohistochemistry
Immunohistochemistry (IHC) was performed on wholemount longitudinal muscle-myenteric
plexus (LMMP) preparations and cross sections of the distal colon. For labelling of nerve fibers
and immune cells, tissues were stored in 50:50 optimum cutting temperature (OCT) com-
pound (Tissue-Tek) and sucrose solution for 24 hours at 4°C and subsequently frozen in liquid
nitrogen-cooled isopentane and OCT compound. Samples were stored at -80°C until they were
cryo-sectioned (30μm) onto glass slides for IHC. After incubation with 10% normal donkey
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serum (NDS) (Merck Millipore) for 1 hour at room temperature, sections were then labelled
with primary antibodies: rabbit anti-β-tubulin (III) (1:1000) and mouse anti-CD45 (1:200)
(both from Abcam) followed by secondary antibodies: donkey anti-rabbit Alexa Fluor 594
(1:200) and donkey anti-mouse FITC 488 (1:200) (both from Jackson Immunoresearch Labo-
ratories). FITC-conjugated anti-human human leukocyte antigen (HLA)-A,B,C antibody
(1:50) (BioLegend) was used to detect the presence of MSCs within the colonic wall. For label-
ling of myenteric neurons in wholemount LMMP preparations, tissues were dissected to
expose the myenteric plexus by removing the mucosa, submucosa and circular muscle layers.
After 1 hour incubation in 10% NDS at room temperature, wholemount preparations were
labelled with primary antibodies: a pan neuronal marker mouse anti-HuC/HuD (1:500)
(Merck Millipore), goat anti-neuronal nitric oxide synthase (nNOS) (1:500) (Novus Biologi-
cals), goat anti-choline acetyltransferase (ChAT) (1:500) (Merck Millipore), mouse anti-CD45
(1:200), and rabbit anti-protein gene product 9.5 (PGP9.5) (1:500) (Abcam) followed by sec-
ondary antibodies: donkey anti-mouse Alexa Fluor 594 (1:200), donkey anti-goat FITC 488
(1:200), donkey anti-mouse FITC 488 (1:200), and donkey anti-rabbit Alexa Fluor 594 (1:200)
(all from Jackson Immunoresearch Laboratories). All tissues were mounted on glass slides with
fluorescent mounting medium (DAKO).
Histology
After fixation, tissues were paraffin embedded, sectioned at 5μm, deparaffinized, cleared, and
rehydrated in graded ethanol concentrations. For haematoxylin and eosin (H&E) staining, sec-
tions were immersed in Xylene (3x4 minutes), 100% ethanol (3 minutes), 90% ethanol, (2 min-
utes), 70% ethanol (2 minutes), rinsed in tap water, haematoxylin (4 minutes), rinsed in tap
water, Scott’s tap water (1 minute), eosin (3 minutes), rinsed in tap water, 100% ethanol (2x1
minute), xylene (2x3 minutes) and mounted on glass slides with distrene plasticizer xylene
(DPX) mountant. Gross morphological damage was blindly assessed by histological grading of
three parameters: mucosal flattening (0 = normal, 3 = severe flattening), occurrence of hemor-
rhagic sites (0 = none, 3 = frequent sites), and variation of the circular muscle (0 = normal,
3 = considerable thickening of muscular layer) [13].
Imaging
Confocal microscopy was performed on an Eclipse Ti confocal laser scanning system (Nikon).
Fluorophores were visualized using a 488 nm excitation filter for Alexa 488 or FITC and a 559
nm excitation filter for Alexa 594 or Rhodamine Red. Z-series images were acquired at a nomi-
nal thickness of 0.5μm (512x512 pixels). The total number of myenteric neurons immunoreac-
tive (IR) for Hu, nNOS, and ChAT, as well as CD45-IR cells were counted within eight
randomly captured images (total area size 2mm2) per preparation at X60 magnification. In
cross sections, the density of nerve fibers was determined by measuring β-tubulin (III)-IR per
2mm2 area with Image J software at X60 magnification. Gross morphological damage in H&E
stained colon sections was visualized using an Olympus BX53 microscope (Olympus) and
images were captured with CellSenseTM software.
Gene expression analysis
Total RNA was extracted from 1x106 BM-MSCs using a High Pure RNA Isolation Kit (Roche)
as per the manufacturer's instructions. cDNA was prepared from 0.5μg RNA using a Super-
Script III First-Strand Synthesis System Reverse Transcriptase-Polymerase Chain Reaction
(RT-PCR) kit and oligo (dT) primers (Invitrogen) (S1 Table). PCR was performed with 1μL
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cDNA and primer pairs under the following cycling conditions: PCR products were resolved
by electrophoresis in 2% agarose gels and the bands visualized under UV light.
Flow cytometric cytokine analysis
MSCs were seeded at a density of 2×104 cells/cm2 in 25cm2 filter cap flasks (Greiner Bio-One).
After 48 hours in culture, samples of the media were collected to analyze the secretion of cyto-
kines. Samples and cytokine standards with known concentrations were prepared according to
the manufacturer’s instructions using the BD™ Cytometric Bead Array (BD Biosciences). Sam-
ples were incubated in the dark with cytokine capture beads and phycoerythrin (PE) detection
reagent for 2 hours each before being transferred to fluorescence activated cell sorting (FACS,
BD Biosciences) tubes; PE fluorescence was measured via a BD FACSCanto II flow cytometer
with FACSDiva v6.1 software.
Antibody array analysis
The RayBio1 Label-based (L-Series) Human Antibody Array 1000 kit was used to determine
presence of proteins secreted from MSCs and was performed following the manufacturer’s
instructions (RayBiotech). Briefly, samples of equal protein concentrations were incubated
with antibody membranes followed by incubation with biotin-conjugated anti-cytokine pri-
mary antibodies, as well as Cy3-conjugated streptavidin. Chemiluminescence was used for sig-
nal detection on a VersaDoc imaging system (Bio-Rad).
Statistical analysis
Data were presented as mean ± standard error of the mean (SEM), if not specified otherwise.
Statistical differences were determined by one-way ANOVA with Bonferroni post hoc test for
multiple group comparisons using Prism v5.0 (GraphPad Software). Data were considered sta-
tistically significant when P<0.05.
Results
MSCs successively migrate transmurally and engraft at the site of
inflammation
To assess the capacity of MSCs homing to the area of tissue damage and inflammation, seg-
ments of the distal colon were collected from guinea-pigs treated with 1) MSCs after TNBS and
2) MSCs only without TNBS. To identify adoptively transferred human MSCs within the
guinea-pig colon, cross sections were labelled with anti-human HLA-A,B,C antibody to detect
major histocompatibility complex class I (MHC class I) antigens which are expressed by all
human nucleated cells (Fig 1). The successful engraftment of MSCs into the colonic wall was
evident by localization of HLA-A,B,C positive cells in the colon sections collected at 6, 24 and
72 hours post induction of colitis (Fig 1A and 1AII). At 6 hours after TNBS administration,
MSCs were present mostly in the mucosal lamina propria in colon sections fromMSC-treated
guinea-pigs (Fig 1A). At 24 and 72 hours after induction of colitis, transmural migration and
engraftment of human MSCs into the colon wall to the level of the myenteric ganglia was evi-
dent (Fig 1AI and 1AII). HLA A,B,C-IR cells were absent in colon sections fromMSC-only
administered animals at all time points indicating that MSC engraftment was not evident in
non-inflamed tissues (Fig 1B and 1BII).
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MSC and CM treatments prevented weight loss in guinea-pigs with
intestinal inflammation
To demonstrate the systemic impact of the tested MSC-based therapies, guinea-pig weight was
monitored daily prior to and post induction of colitis and/or treatments (Fig 2, S2 Table).
Sham-treated guinea-pigs consistently gained weight over 72 hours. At 6 hours after TNBS
administration there was no change in weight between all groups. At 24, 48 and 72 hours after
induction of inflammation, significant weight loss was observed in the TNBS groups and UCM
groups compared to sham-treated animals (P<0.05). MSC and CM-treated animals consis-
tently gained weight from 6 to 72 hours post induction of colitis similar to sham-treated
guinea-pigs.
MSC and CM treatments accelerated repair of damaged colonic
architecture
Gross morphological assessment of H&E-stained colon sections enabled definition of changes
to colonic architecture 6, 24 and 72 hours after induction of TNBS-colitis (Fig 3). H&E-stained
colon cross sections from sham-treated guinea-pigs displayed normal structural arrangements
of goblet cells and crypts, a continuous epithelial cell lining and distinct colonic layers at 6,
24 and 72 hours post treatment (histological score 0–1) (Fig 3A–3AII). Conversely, examina-
tion of distal colon sections from guinea-pigs in the TNBS-only group showed immune cell
Fig 1. MSC homing within the inflamed colon.Migration and homing of human bone marrow MSCs to the inflamed area of the guinea-pig colon was
confirmed using anti-HLA-A,B,C antibody specific to humanMHC class I. MSCs administered 3 hours after TNBS application were localized mostly in the
lamina propria 6 hours after induction of colitis (A). Transmural engraftment of humanMSCs into the colon wall to the level of the myenteric ganglia was
evident 24 and 72 hours post induction of colitis (AI-AII). At 6, 24 and 72 hours, HLA-A,B,C-IR cells were not detected in the distal colon fromMSC-only
treated guinea-pigs, validating absence of MSC homing to non-inflamed tissues (B-BII). n = 3/group/time point. Scale bars = 50μm.
doi:10.1371/journal.pone.0139023.g001
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infiltration and accumulation in the crypts and submucosal layers, goblet cell loss, glandular
disruption and flattening, muscular edema and complete destruction of the epithelial cell lining
at 6 hours (Fig 3B). Immune cell accumulation, flattening of glands and crypt distortion perse-
vered 24 hours post induction of colitis (Fig 3BI). Some regeneration of the epithelium had
occurred by 72 hours in TNBS-only administered animals; crypt morphology remained dis-
torted, but infiltrates of immune cells were less prominent compared to 24 hours (Fig 3BII).
Grading of gross morphological parameters in colon sections from TNBS-administered ani-
mals indicated histological score = 3 at 6 hours and score = 2–3 at 24 and 72 hours following
induction of inflammation. Some disruption to glandular structure and epithelial cell lining
was observed in colon sections fromMSC and CM-treated guinea-pigs at 6 hours after induc-
tion of colitis (histological score = 1–2) (Fig 3C and 3D). However, mucosal healing and less
flattening of crypts was evidenced when compared to sections from TNBS-only administered
guinea-pigs. At 24 hours post induction of inflammation, sections fromMSC and CM-treated
animals revealed accelerated mucosal healing and repair to levels comparable with sham-
treated animals (Fig 3CI–3DI). Furthermore, at the 72 hour time point, no evidence of mucosal
damage and disruption to the colonic architecture in MSC-treated and CM-treated colon sec-
tions was present (histological score = 0–1) (Fig 3CII–3DII). Sections from UCM-treated ani-
mals displayed morphological damage similar to the TNBS-only group at 6 and 24 hour time
points including immune cell infiltration, goblet cell loss, glandular distortion and flattening,
muscular edema and destruction of the epithelial cell lining (histological score = 3) (Fig 3E and
3EI). After 72 hours, flattening of the glands and muscular edema was still evident similar to
Fig 2. Body weight of guinea-pigs within 72 hours post induction of colitis or sham treatment. No change in guinea-pig weight was observed in all
groups at the 6 hour time point. Within 72 hours, administration of TNBS-only and treatment with UCM induced significant loss of body weight, while
treatment with MSCs and CM after the induction of colitis prevented loss of body weight. n = 4/group/time point. *P<0.05 compared to sham, MSC and CM-
treated groups, ^P<0.05 compared to sham and MSC-treated groups.
doi:10.1371/journal.pone.0139023.g002
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TNBS-only administered animals, however some signs of mucosal repair were observed (histo-
logical score = 2–3) (Fig 3EII).
MSC and CM treatments attenuated the immune response in the distal
colon 24 hours after induction of inflammation
To measure the severity of colitis and the anti-inflammatory efficacy of the treatments, quanti-
tative analyses of CD45+ leukocytes were performed in colon cross sections and wholemount
LMMP preparations. Considerably greater numbers of CD45-IR cells were present in the colon
sections from TNBS-only (369±10 cells/area), MSC (304±14 cells/area), CM (297±4 cells/area)
and UCM-treated (379±10 cells/area) animals compared to sham-treated (122±4 cells/area)
animals at the 6 hour time point (P<0.001 for all, Figs 4A–4E and 5A). At 24 hours, the num-
bers of CD45-IR cells were reduced in colon sections fromMSC (141±7 cells/area) and CM-
treated (142±9 cells/area) guinea-pigs and were similar to the number of CD45-IR cells in sec-
tions from sham-treated (120±3 cells/area) animals. The numbers of leukocytes in colon sec-
tions from TNBS-only (379±6 cells/area) and UCM-treated (361±10 cells/area) animals
remained elevated compared to sham, MSC and CM-treated groups (P<0.001 for all; Figs 4AI–
4EI and 5A). CD45-IR cells were identified throughout the thickness of the colon in sections
from TNBS-only and UCM-treated animals compared to sections from other groups. The
numbers of CD45-IR cells in sections from TNBS-only (301±5 cells/area) and UCM-treated
(279±7 cells/area) guinea-pigs were slightly reduced by 72 hours, but were still higher com-
pared to the number of leukocytes in the sections from sham (121±4 cells/area), MSC (121±2
cells/area) and CM-treated (118±2 cells/area) guinea-pigs (P<0.001 for all, Figs 4AII–4EII and
5A).
Immune cell infiltration to the level of myenteric ganglia was quantified in wholemount
LMMP preparations by double labelling with anti-CD45 antibody and pan-neuronal marker
anti-PGP9.5 antibody (Fig 6). At 6 hours, quantitative analysis of immune cells per 2mm2 area
showed similar numbers of CD45-IR cells in LMMP preparations of the colon from sham (19
±1 cells/area), TNBS-only (26±3 cells/area), MSC (22±2 cells/area), CM (22±1 cells/area), and
UCM-treated animals (23±3 cells/area, Fig 5B). After 24 hours, the number of leukocytes at the
level of the myenteric plexus was greater in tissues from TNBS-only (108±7 cells/area) and
UCM-treated (100±3 cells/area) animals compared to sections from sham (19±1 cells/area),
MSC (39±3 cells/area) and CM-treated (47±3 cells/area) guinea-pigs (P<0.001 for all; Figs 5B
and 6AI–6EI). However, the numbers of CD45+ cells in colon preparations fromMSC and
CM-treated animals were higher than in preparations from sham-treated guinea-pigs (MSC:
P<0.05, CM: P<0.01). By 72 hours after induction of inflammation, the numbers of immune
cells at the level of the myenteric ganglia in colon preparations fromMSC (23±2 cells/area)
and CM-treated (27±1 cells/area) animals were comparable to the number of immune cells in
preparations from sham-treated (19±1 cells/area) guinea-pigs. The quantity of CD45+ cells in
preparations of the distal colon from TNBS-only (77±7 cells/area) and UCM-treated (74±2
Fig 3. Grossmorphological changes in the distal colon assessed in H&E stained cross sections. An
intact epithelial lining and systematic arrangement of colonic layers were evident in sections from sham-
treated animals at all time points (A-AII). Immune infiltrate, flattening of the glands, disruption to the epithelial
lining and destruction of mucosal epithelium, goblet cell loss and muscular edema were observed in colon
tissues from TNBS-administered (B-BII) and UCM-treated (E-EII) guinea-pigs at all time points. Sections from
MSC and CM-treated animals revealed initiation of colonic repair at 6 hours post induction of colitis (C-D).
Restoration of colonic architecture was observed at 24 (CI-DI) and 72 hours (CII-DII). n = 4/group/time point.
Scale bars = 50μm.
doi:10.1371/journal.pone.0139023.g003
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cells/area) animals at 72 hours was higher when compared to sham, MSC, and CM-treated
guinea-pigs (P<0.001 for all, Figs 5B and 6AII–6EII).
MSC and CM treatments facilitated re-growth of nerve fibers and
protected against neuronal loss 24 hours after induction of colitis
Cross sections of the guinea-pig distal colon were labelled with antibody specific to neuronal
microtubule protein β-tubulin (III) which identifies neuronal cell bodies and processes inner-
vating smooth muscles and mucosa (Fig 7). Orderly distribution of β-tubulin (III)-IR fibers
within the mucosal gland cores, submucosal and muscular layers were observed in colon sec-
tions from sham-treated guinea-pigs at all time points (Fig 7A–7AII). Quantification of fiber
density demonstrated the total area of β-tubulin (III)-IR fibers in sections from sham-treated
animals was 10.5±1.4%, 10.7±1.3% and 10.4±1.4% at 6, 24 and 72 hours after treatment,
respectively (Fig 8A). At all time points following TNBS administration, β-tubulin (III)-IR
fibers in colon sections from animals in the TNBS-only and UCM-treated groups were disorga-
nized, fragmented, and dispersed irregularly within the mucosa (Fig 7B–7BII and 7E–7EII).
Compared to sections from sham-treated animals, quantitative analysis revealed lower β-tubu-
lin (III)-IR fiber density at all time points in colon sections from TNBS-only (6 hours: 6.6
±1.3%, P<0.001, 24 hours: 6.3±1.4%, P<0.001, 72 hours: 6.8±1.4%, P<0.01) and UCM-treated
(6 hours: 6.6±1.4%, 24 hours: 6.5±1.3%, 72 hours: 6.3±1.5%, P<0.001 for all) guinea-pigs
(Fig 8A). Treatment with MSCs and CM did not prevent damage to the nerve fibers 6 hours
after TNBS administration; the density and organization of fibers in sections from MSC and
CM-treated animals were similar to sections from TNBS-only and UCM-treated guinea-pigs
(Fig 7C–7DII). Subsequently, the density of β-tubulin (III)-IR fibers in sections fromMSC
(7.9±1.3%) and CM-treated (7.9±1.4%) animals at the 6 hour time point was less when com-
pared to sham-treated animals (P<0.05 for both, Fig 8A). This result suggests that 6 hours is
insufficient time for the regenerative effect of MSC-based treatments to occur. The density of
β-tubulin (III)-IR fibers in colon sections from MSC and CM-treated guinea-pigs were compa-
rable to those in sections from sham-treated animals at the 24 (MSC: 9.7±1.4%, CM: 9.6±1.4%)
and 72 hour time points (MSC: 9.6±1.4%, CM: 9.7±1.4%) (Figs 7CI–7DII and 8A). β-Tubulin
(III)-IR fiber density in colon sections fromMSC and CM-treated guinea-pigs was higher
when compared to sections from TNBS-only and UCM-treated animals at 24 (P<0.01 for
both) and 72 hours (P<0.05 for both), but not after 6 hours (Fig 8A). Thus, MSC and CM
treatments facilitated fiber regeneration and axonal re-growth 24 and 72 hours after induction
of inflammation.
To study the effects of MSC and CM treatments on the number of myenteric neurons, neu-
ronal cell bodies were labelled with the pan-neuronal marker anti-Hu antibody in wholemount
LMMP preparations of the distal colon (Fig 9). The number of Hu-IR neurons counted within
a 2mm2 area did not differ between all groups at 6 hours (sham: 264±2 cells/area, TNBS: 260±3
cells/area, MSC: 264±2 cells/area, CM: 264±1 cells/area, UCM: 262±1 cells/area) (Figs 8B
and 9A–9E). At 24 hours after induction of colitis, the number of Hu-IR myenteric neurons
decreased in colon preparations from TNBS-only (205±9 cells/area) and UCM-treated (209±7
Fig 4. Leukocyte infiltration in colon cross sections. Cross sections of the distal colon were labelled with
pan-leukocyte marker anti-CD45 antibody. At 6 hours, an increase in CD45-IR cells was observed in the
mucosa of TNBS-only, MSC, CM and UCM-treated sections compared to sections from sham-treated
animals (A-E). At 24 and 72 hours, elevated numbers of CD45-IR cells were prominent transmurally through
the layers of the colon wall in TNBS-only (BI-BII) and UCM-treated (EI-EII) cross sections. Treatment with
MSCs and CM attenuated the increase of CD45-IR cells at 24 (CI-DI) and 72 hours (CII-DII). n = 4/group/time
point. Scale bars = 50μm.
doi:10.1371/journal.pone.0139023.g004
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Fig 5. Quantitative analysis of leucocyte numbers in colon cross sections and wholemount preparations. Total number of leukocytes counted per
2mm2 area within the colon wall in cross sections (A). Total number of leukocytes quantified per 2mm2 area in LMMP preparations (B). n = 4/group/time
point. ^P < .05, ^^P < .01, ^^^P < .001 compared to sham-treated group. ***P < .001 compared to sham, MSC and CM-treated groups.
doi:10.1371/journal.pone.0139023.g005
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cells/area) guinea-pigs compared to sham-treated animals (260±2 cells/area, P<0.001 for
both). MSC and CM treatments attenuated neuronal loss associated with intestinal inflamma-
tion at 24 hours (MSC: 260±3 cells/area, CM: 255±4 cells/area) (Figs 8B and 9AI–9EI). At 72
hours, a reduction in the number of Hu-IR neurons was observed in LMMP preparations of
the distal colon from TNBS-only (202±5 cells/area) and UCM-treated (212±5 cells/area)
guinea-pigs compared to preparations from sham (261±4.9 cells/area), MSC (260±7 cells/
area), and CM-treated (254±5 cells/area) animals (P<0.001 for all, Figs 8B and 9AII–9EII).
Effects of MSC and CM treatments on inhibitory and excitatory neurons
in the distal colon
Changes in inhibitory and excitatory myenteric neurons underlie inflammation-induced
colonic dysmotility (16–18); therefore we investigated the effects of MSC-based therapies on
these neurons. Inhibitory neurons were identified by using nNOS immunoreactivity in whole-
mount LMMP preparations of the distal colon (Fig 10). The number and proportion of nNO-
S-IR neurons were comparable between all groups at the 6 hour time point (sham: 54±2 cells/
area, 20±1%, TNBS: 57±3 cells/area, 22±1%, MSC: 57±2 cells/area, 22±2%, CM: 56±2 cells/
area, 21±2%, UCM: 57±3 cells/area, 22±3%, Figs 10A–10E and 11). At 24 hours, the quantity
of nNOS-IR myenteric neurons increased in the colon in TNBS-only (65±1 cells/area) and
UCM-treated (66±3 cells/area) guinea-pigs compared to sham (53±1 cells/area), MSC (53±2
cells/area) and CM-treated (55±2 cells/area) animals (P<0.001 for all; Figs 10AI–10EI and
11A). The proportion of nNOS-IR neurons to the total number of neurons 24 hours post
induction of colitis was greater in TNBS-only (31.9±1.8%) and UCM-treated (31.7±1.2%)
guinea-pigs compared to sham (20±0.5%), MSC (21±1%), and CM-treated (22±1%) animals
(P<0.001 for all; Fig 11B). At 72 hours, the number of nNOS-IR neurons in preparations of the
distal colon from TNBS-only (65±3 cells/area) and UCM-treated (64±2 cells/area) guinea-pigs
was higher compared to sham (53±1 cells/area), MSC (54±2 cells/area) and CM-treated (54±2
cells/area) animals (P<0.05 for all; Figs 10AII–10EII and 11A). The proportion of nNOS-IR
neurons at 72 hours was greater in colon preparations from TNBS-only (32±2%) and UCM-
treated (30±0.5%) guinea-pigs compared to sham (20±0.5%), MSC (21±1%), and CM-treated
(21±1%) animals (P<0.001 for all; Fig 11B).
Excitatory neurons were identified using ChAT immunoreactivity in wholemount prepara-
tions of the distal colon (Fig 12). The number of ChAT-IR neurons was similar in preparations
from all groups at the 6 hour time point (sham: 156±2 cells/area, TNBS: 156±3 cells/area,
MSC: 152±3 cells/area, CM: 153±2 cells/area, UCM: 146±2 cells/area, Figs 12A–12E and 13A).
The number of ChAT-IR neurons decreased at the 24 and 72 hour time points in TNBS-only
and UCM-treated groups (24 hours, TNBS: 108±2 cells/area, UCM: 115±2 cells/area; 72 hours,
TNBS: 111±5 cells/area, UCM: 115±12 cells/area) compared to sham (24 hours: 158±7 cells/
area, 72 hours: 155±2 cells/area), MSC (24 hours: 155±2 cells/area, 72 hours: 150±4 cells/area)
and CM (24 hours: 147±3 cells/area, 72 hours: 150±4 cells/area) groups (P<0.001 for all). The
number of ChAT-IR neurons was unaffected at 24 and 72 hours in MSC and CM-treated
Fig 6. Infiltration of leukocytes to the level of the myenteric plexus post induction of colitis.CD45-IR
cells in LMMP colon preparations. At 6 hours, a low level of leukocyte infiltration around the myenteric ganglia
was observed in all groups (A-E). At 24 hours, leukocyte infiltration in LMMP preparations from TNBS-only
(BI) and UCM-treated (EI) animals was elevated in comparison to sham (AI), MSC (CI) and CM-treated (DI)
groups. CD45-IR cells were still evident at 72 hours in preparations from TNBS-only (BII) and UCM-treated
(EII) animals. Leukocytes in preparations fromMSC and CM-treated groups returned to sham-treated levels
by 72 hours (CII-DII). n = 4/group/time point. Scale bars = 100μm.
doi:10.1371/journal.pone.0139023.g006
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groups (Figs 12AI–12EII and 13A). There were no differences between any groups in the pro-
portion of ChAT-IR neurons to total number of neurons at all time points (Fig 13B).
Neuroprotective factors released by MSCs
RT-PCR, flow cytometry and antibody array analysis of factors in conditioned medium
revealed that MSCs used in our study released a substantial number of growth factors, cyto-
kines and proteins exerting neuroprotective effects. Expression of factors with well-known neu-
roprotective functions have been detected by highly sensitive RT-PCR and flow cytometry
techniques. The antibody array method was less sensitive than RT-PCR and flow cytometry,
however the capacity to detect great amount of different target proteins enabled to identify
many other neuroprotective factors released by MSCs (S3 Table).
Discussion
The objective of this study was to determine the time point at which MSC-based therapies initi-
ate their effects in the guinea-pig model of TNBS-induced colitis. The present study showed
that MSC and CM treatments 1) prevented weight loss, 2) accelerated repair of colonic archi-
tecture, 3) reduced immune infiltrate both in the mucosa and at the level of the myenteric gan-
glia, 4) accelerated regeneration of nerve fibers and 5) attenuated the loss of myenteric neurons
and changes in their subpopulations. Substantial number of neuroprotective factors released by
MSCs has been detected in their secretome. Overall, prominent effects of MSC-based therapies
were observed 24 hours after induction of inflammation in the guinea-pig model of TNBS-
induced colitis.
We utilized human BM-MSCs since they are the best characterized and most established as
a viable cellular therapy for many pathological conditions in both animal and clinical studies
[58]. In our study, BM-MSCs were administered 3 hours after TNBS when the most significant
damage to the mucosa occurs [57]. Timing of administration can impact MSC efficacy [59]
and previous studies have shown that MSC transplantation at earlier phases of inflammation
are optimal for therapeutic effects [60–62].
Viable human MSCs constitutively express MHC class I molecules on their surface at mod-
erate levels [63] and can escape immune rejection when transplanted into guinea-pigs, as well
as other species without the necessity of host immunosuppression [64]. It is known that che-
mokine receptors and adhesion molecules expressed by MSCs respond to chemoattractant sig-
nals from sites of injury facilitating MSC migratory and homing capacity [60]. We employed
immuno-labelling of colon cross sections with anti-HLA-A,B,C antibody to evaluate the suc-
cessful migration and engraftment of MSCs within the inflamed colon wall. Results of our
study verified the migratory capacity of MSCs throughout the layers of the inflamed colon, but
not to the uninflamed colon. Progressive MSC homing towards inflamed sites is evidenced by
their presence in the colonic mucosa at 6 hours after induction of colitis and at the level of the
myenteric plexus by 24 hours and 72 hours post inflammation.
The successful migration and engraftment of enema-applied MSCs into the inflamed
colonic wall observed in our study is consistent with previous reports demonstrating
Fig 7. Nerve fibers in cross sections of the distal colon.Orderly distribution of fibers labelled by neuron
specific anti-β-tubulin (III) antibody was observed in colon sections from sham-treated guinea-pigs at all time
points (A-AII). Disorganized, fragmented, and irregularly dispersed fibers were evident within the mucosa of
sections from TNBS-only (B-BII) and UCM-treated (E-EII) animals at all time points. Damage to nerve fibers
was present in sections fromMSC and CM-treated animals at 6 hours (C-D), however re-growth of nerve
fibers was observed at 24 (CI-DI) and 72 hours (CII-DII). n = 4/group/time point. Scale bars = 50μm.
doi:10.1371/journal.pone.0139023.g007
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Fig 8. Quantitative analysis of nerve fiber density and the total number of neurons in the myenteric ganglia.Nerve fiber density quantified per 2mm2
area in cross sections of the distal colon (A). The total number of myenteric neurons per 2mm2 area in LMMP wholemount preparations (B). n = 4/group/time
point. ^P < .05, ^^P < .01, ^^^P < .001 compared to sham-treated group. *P < .05, **P < .01, ***P < .001 compared to MSC and CM-treated groups.
doi:10.1371/journal.pone.0139023.g008
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implantation of locally administered MSCs into target tissues, especially in inflammatory con-
ditions [44, 51]. However, enema application is less invasive than administration of MSCs into
the injury site, such as injection directly into the colonic wall [44], and is safe, convenient and
feasible for IBD patients without complications. Furthermore, enema application is a plausible
administration route for CM treatments.
Weight loss associated with TNBS-induced colitis was observed in our study and is consis-
tent with other reports [12, 20]. MSC-based therapies effectively attenuated weight loss at 24
hours post induction of colitis and at subsequent time points. Furthermore, administration of
MSCs or CM into the distal colon ameliorated epithelial and goblet cell loss, as well as repaired
colonic architecture by 24 hours after induction of colitis and was maintained for at least 72
hours. These findings are consistent with previous reports on the therapeutic efficiency
of MSCs in other animal models of colitis where MSCs and CM have been shown to
protect against ulceration, necrosis of epithelial tissue, and increased permeability of the
mucosa [44, 45].
As we have shown in our model of experimental colitis, MSCs reduce leukocyte infiltrate
which is also observed in other disease models [32, 45, 59]. The immunomodulatory mecha-
nisms however, have not been fully elucidated, although it is considered to be through either
the production of various soluble factors or by direct interaction with target cells [36, 65].
MSCs exhibit potent modulatory effects on immune cells including T and B lymphocytes, nat-
ural killer cells and dendritic cells [66, 67]. The ability of MSCs to exert their immunosuppres-
sive function requires MSC activation in a pro-inflammatory microenvironment [68]. Our
results indicated that MSC and CM treatments were effective within 24 hours post inflamma-
tion as confirmed by reduced leukocyte numbers throughout the distal colon wall. MSCs were
able to continue inhibition of CD45-IR cells for 72 hours and can exert long lasting effects up
to 7 days as shown in our previous study [18]. Infiltration of leukocytes to the level of myen-
teric ganglia was reduced in MSC and CM treated groups at 24 hours post induction of colitis,
but was still higher than in the sham treated group. The level of CD45-IR cells was comparable
to the sham group only by 72 hours.
Our study demonstrated a loss of myenteric neurons at 24 hours post induction of colitis. A
reduction in the quantity of myenteric neurons following TNBS administration is consistent
with previous studies in the guinea-pig intestine [10, 15]. Neuronal numbers were unaffected
at 6 hours which is consistent with previous findings reporting no change in the total number
of myenteric neurons 6 hours after TNBS administration [10]. MSC and CM treatments pre-
vented the neuronal loss associated with TNBS-induced inflammation. The number of myen-
teric neurons in MSC and CM-treated groups was unchanged at all time points even though
the quantity of leucocytes at the level of the myenteric ganglia remained increased at 24 hours.
This indicates that MSC-based therapies are capable of exerting neuroprotective effects inde-
pendent of anti-inflammatory actions. Some studies have reported the capacity of MSCs to dif-
ferentiate into cells of neuronal and glial lineage [34, 35]. Despite evidence that MSCs have the
ability to differentiate into neurons and glial cells after appropriate induction in vitro, it has
been shown that MSCs transplanted into the damaged central nervous system infrequently dif-
ferentiate into neural phenotypes [69, 70]. Limited cellular telomerase activity and a maximum
Fig 9. Effects of MSC and CM treatments on the total number of myenteric neurons.Myenteric neurons
were identified by anti-Hu antibody in wholemount preparations of the distal colon. At 6 hours post TNBS
administration, the number of myenteric neurons was similar across all groups (A-E). At 24 and 72 hours,
significant loss of neurons was observed in sections from TNBS-only (BI-BII) and UCM-treated (EI-EII)
compared to sections from sham-treated (AI-AII) animals, but not in MSC (CI-CII) and CM-treated (DI-DII)
groups. n = 4/group/time point. Scale bars = 50μm.
doi:10.1371/journal.pone.0139023.g009
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72 hour time point in the current study constrained the likelihood of observing any in vivo
MSC differentiation into specific cell lineages [71–73].
In addition to preventing a reduction in the total number of myenteric neurons, MSCs
accelerated regeneration and re-growth of nerve fibers in the colon. Damage to the nerve fibers
was observed in all groups at 6 hours after induction of inflammation. However, in MSC and
CM treated animals, re-growth of axons was evident by 24 hours and nerve fiber density
returned to sham levels at 72 hours. Promotion of axonal re-growth by MSC-based therapies
within this study is consistent with previous findings in models of spinal cord injury [74, 75].
Our study revealed an increase in the number of nNOS neurons, as well a decrease in the
number of ChAT neurons at 24 hours after induction of colitis. These results are comparable
to previous studies in TNBS and dextran sodium sulphate animal models of colitis, as well as in
tissues from IBD patients reporting changes in neurochemical coding of enteric neuronal sub-
populations [10, 16, 17, 76, 77]. Nitrergic (nNOS) neurons in the myenteric plexus are primar-
ily inhibitory motor neurons responsible for the relaxation of intestinal smooth muscle, while
cholinergic (ChAT) neurons are the major excitatory motor neurons of the ENS [7]. Imbal-
ances in numbers of nNOS and ChAT neurons associate with impaired smooth muscle con-
tractility and intestinal dysmotility [17]. We found that MSC-based therapies alleviated the
inflammation-induced increase in nNOS neurons and loss of ChAT neurons in the myenteric
plexus at 24 and 72 hours. These results are consistent with our previous study in which
MSC-based therapies attenuated changes in subpopulations of nNOS and ChAT myenteric
neurons and colon dysfunction 7 days post treatment [18].
We found that the efficacy of CM treatment was comparable to MSC therapy. Previous find-
ings in nervous system injury and other pathological conditions highlight the therapeutic
potential of soluble factors released by MSCs [36, 78–83]. It is now considered that the protec-
tive mechanisms and endogenous regeneration initiated by MSCs is due to their ability to
produce and secrete a wide range of bioactive soluble factors acting as paracrine mediators;
directly stimulating target cells and/or instigating nearby cells to release functionally active
agents [84]. The MSC secretome contains anti-apoptotic, neurotrophic and growth factors, as
well as neurotransmitters and can promote stimulation of axonal growth, microglial regulation,
immunomodulation and re-myelination of host axons [85–87].
The MSC secretome may be responsible for the therapeutic effect observed in this study via:
1) immunomodulation by reducing in vivo levels of pro-inflammatory mediators while simul-
taneously increasing the production of anti-inflammatory factors in the gut and serum and/or
2) direct neuroprotection of enteric neurons via release of neurotrophic factors. During an
inflammatory flare, an array of cytokines and chemokines, reactive oxygen and nitrogen spe-
cies, prostaglandins and other pro-inflammatory mediators induce profound structural and
functional damage to the ENS [88–91]. Previous studies in experimental colitis have demon-
strated that MSC treatment stimulates upregulation of anti-inflammatory factors including
interleukin (IL)-10, indoleamine 2,3-dioxygenase, prostaglandin E2, and transforming growth
factor-β1, as well as a downregulation of pro-inflammatory mediators such as IL-1β, IL-6, IL-
12, IL-17, interferon-γ and tumor necrosis factor-α [67, 92, 93]. This immunomodulatory
effect of MSC therapy could in turn prevent and/or reduce the damage to enteric neurons and
nerve fibers. A direct MSC effect for maintaining enteric neuronal integrity during intestinal
inflammation may occur via release of neurotrophic and neuroprotective agents in the MSC
Fig 10. Effects of MSC and CM treatments on nNOS-IR myenteric neurons. No changes in nNOS-IR
neurons were observed at 6 hours in any group (A-E). At 24 and 72 hours, an increase in nNOS-IR neurons
was observed in sections from TNBS-only (BI-BII) and UCM-treated (EI-EII) animals compared to sham (AI-
AII), but not in MSC and CM-treated groups (CI-CII, DI-DII). n = 4/group/time point. Scale bars = 50μm.
doi:10.1371/journal.pone.0139023.g010
MSC Therapy and Colitis-Induced Enteric Neuropathy
PLOS ONE | DOI:10.1371/journal.pone.0139023 September 23, 2015 22 / 32
Fig 11. Quantification of the number and proportion of nNOS-IRmyenteric neurons. The total number of nNOS-IR neurons identified by anti-nNOS
antibody per 2mm2 area (A). The proportion of nNOS-IR neurons to the total number of neurons (B). n = 4/group/time point. *P < .05, **P < .01, ***P < .001
compared to sham, MSC and CM-treated groups.
doi:10.1371/journal.pone.0139023.g011
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Fig 12. Effects of MSC and CM treatments on ChAT-IR myenteric neurons.No changes in the number of
ChAT-IR myenteric neurons was observed in any group at 6 hours (A-E). Significant loss of ChAT-IR neurons
was observed in sections from TNBS-only and UCM-treated animals at 24 and 72 hours (BI-BII, EI-EII). The
number of ChAT-IR myenteric neurons was unaffected in MSC and CM-treated groups at 24 and 72 hours
(CI-CII, DI-DII). n = 4/group/time point. Scale bars = 50μm.
doi:10.1371/journal.pone.0139023.g012
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Fig 13. Quantification of the number and proportion of ChAT-IRmyenteric neurons. The total number of ChAT-IR neurons quantified per 2mm2 area
(A). The proportion of ChAT-IR neurons to the total number of neurons (B). n = 4/group/time point. ***P < .001 compared to sham, MSC and CM-treated
groups.
doi:10.1371/journal.pone.0139023.g013
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secretome. In this study, analysis of conditioned medium revealed that MSCs released consid-
erable number of factors under normal culturing conditions including those that have been
demonstrated to be neurotrophic and neuroprotective for enteric neurons as well as factors
that have not been studied in the ENS. Previous studies have shown that glial-derived neuro-
trophic factor protects enteric neurons from apoptosis and promotes the development and sur-
vival of many types of neurons [6, 94–97]. Other factors, such as neurotrophin, nerve growth
factor, brain-derived neurotrophic factor, ciliary neurotrophic factor and leukemia inhibitory
factor are also involved in modulation of gut inflammation and colonic sensitivity [94, 95]. In
our study neurotrophic and neuroprotective factors were detected in the secretome of naïve
MSCs (not exposed to inflammatory conditions). It is plausible that upon placement in an
inflammatory milieu MSCs release a wider array of factors than we have reported in this study.
The role of specific MSC-secreted neuroprotective factors in preventing enteric neuronal loss
and damage caused by intestinal inflammation needs to be further elucidated.
In conclusion, this study confirmed that BM-MSCs and CM have the ability to prevent
inflammatory insults to the ENS when administered 3 hours after induction of colitis. Our
results clearly support the therapeutic potential of enema-administered MSC and CM treat-
ments for preventing enteric neuropathy associated with TNBS-induced colitis as early as 24
hours after induction of inflammation even though the inflammatory reaction at the level of
the myenteric ganglia has not completely subsided at this time point. This suggests that the
neuroprotective efficacy of MSC-based therapies can be exerted independently to their anti-
inflammatory effects. Further investigations need to be conducted to define the pathways and
specific factors contributing to enteric neuroprotection by MSC-based treatments in acute and
chronic inflammatory conditions.
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